Notably, FLT3 (FMS-like tyrosine kinase 3) pathway inhibitors, such as G749, could downregulate ANXA9 expression by inhibiting ZMYM2, potentially overcoming treatment failure in CRC patients. Here, ANXA9 is linked to colorectal carcinoma.